Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “lung cancer”
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belgium, Brazil +24 more
- Facilitation of Information eXchange for Shared Decision Making for Lung Cancer ScreeningEnrolling By Invitation
Sponsor: University of Massachusetts, Worcester
Lung Cancer Screening
United States
- Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active Not Recruiting
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · Solid Tumors · Programmed Cell Death-1 (PD1, PD-1) · Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Japan
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer · Lung Cancer · Gastrointestinal Cancer
United States
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive Not Recruiting
Sponsor: AstraZeneca
Carcinoma · Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +22 more
Sponsor: Daiichi Sankyo
Small Cell Lung Cancer
United States, Australia, Austria, Belgium, Brazil +18 more
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)Recruiting
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm Malignant
United States, Brazil, Chile, China, Germany +6 more
Sponsor: University of Washington
Metastatic Lung Non-Small Cell Carcinoma · Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
United States
Sponsor: Nuvalent Inc.
Non Small Cell Lung Cancer · ALK-positive Non-small Cell Lung Cancer (NSCLC)
United States, Australia, Canada, France, Italy +7 more
- Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling By Invitation
Sponsor: National Cancer Institute (NCI)
Solid Tumors · Hematologic Malignancy · Gastrointestinal Cancer · Liver Cancer
United States
Sponsor: Washington University School of Medicine
Early Stage Non-small Cell Lung Cancer · Non-small Cell Lung Cancer
United States
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesRecruiting
Sponsor: Reunion Neuroscience Inc
Adjustment Disorder
United States
- Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot Yet Recruiting
Sponsor: Guangdong Association of Clinical Trials
ALK Positive Non-small Cell Lung Cancer
China
Sponsor: Nanjing First Hospital, Nanjing Medical University
Nerve Block · Thoracoscopic Radical Resection of Lung Cancer
China
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer · KRAS G12C Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +23 more
- A Study of IOV-5001 in Adults With Advanced Solid TumorsNot Yet Recruiting
Sponsor: Iovance Biotherapeutics, Inc.
Advanced Solid Tumors · Non-Small Cell Lung Cancer · Triple Negative Breast Cancer (TNBC) · Colorectal Cancer
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer
China
- Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Active Not Recruiting
Sponsor: AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
United States, Argentina, Brazil, Bulgaria, Chile +24 more
Sponsor: University Health Network, Toronto
Non-Small Cell Lung Cancer · Radiation Induced Lung Injury (RILI)
Canada
Sponsor: University of Illinois at Chicago
Lung Cancer Screening
United States
Sponsor: AstraZeneca
Non-small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Colorectal Carcinoma · Pancreatic Adenocarcinoma
United States
Sponsor: Pheon Therapeutics
Colon Cancer · Pancreatic Cancer · Lung Cancer (NSCLC) · Advanced Cancer
United States, South Korea, Spain
- Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active Not Recruiting
Sponsor: AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
United States, Australia, Belgium, Canada, France +12 more
- Precision Prevention Strategy to Increase Uptake and Engagement in Lung Cancer Screening and Smoking Cessation TreatmentEnrolling By Invitation
Sponsor: Washington University School of Medicine
Smoking · Smoking Cessation · Tobacco Use Cessation
United States
Sponsor: University of Pennsylvania
Cholangiocarcinoma · Colorectal Cancer · Non-Small Cell Lung Cancer · Pancreatic Adenocarcinoma
United States